Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.64), $0.14 better than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Worthington Industries (WOR) Misses Q4 EPS by 9c
• Crown Crafts (CRWS) Reports Q4 EPS of $0.03